Welcome to our dedicated page for Medicure news (Ticker: MCUJF), a resource for investors and traders seeking the latest updates and insights on Medicure stock.
Medicure (MCUJF) delivers innovative therapeutic solutions through pharmaceutical development and direct-to-consumer pharmacy services. This page provides authorized updates on the company's clinical advancements, regulatory milestones, and strategic business decisions.
Access real-time press releases covering earnings reports, drug development progress (including MC-1 clinical trials), and operational expansions like the Gateway Medical Pharmacy acquisition. Investors will find essential updates on Marley Drug's nationwide distribution network and regulatory designations such as Orphan Drug statuses.
Our curated news feed serves as a comprehensive resource for tracking Medicure's dual focus on cardiovascular treatments and neurometabolic disorder solutions. Stay informed about product commercialization efforts, intellectual property developments, and compliance achievements that shape the company's market position.
Bookmark this page for verified updates on Medicure's pharmaceutical innovations and pharmacy service enhancements. Check regularly for new developments in therapeutic research and healthcare distribution strategies.
Medicure Inc. (OTC PINK: MCUJF) reported its financial results for the year and quarter ending December 31, 2022. The company achieved a total net revenue of $23.1 million, up from $21.7 million in 2021. For Q4 2022, revenue was $6.3 million, slightly down from $6.8 million in Q4 2021. Key revenue drivers included AGGRASTAT® sales of $11.7 million and ZYPITAMAG® sales of $3.6 million. Adjusted EBITDA increased to $3.3 million from $2.1 million in the prior year. Net income was reported at $1.4 million or $0.13 per share, compared to a loss of $727,000 in 2021. Despite the positive overall financial performance, Medicure made a marketing hold on sodium nitroprusside due to poor commercial viability.
Medicure Inc. (OTC PINK: MCUJF) will announce its 2022 Year End Financial Results via a conference call on April 10, 2023, at 8:30 AM ET. These results will be filed after market close on April 6, 2023. The call will include a Q&A session for stakeholders to address financial performance and operational questions. Medicure specializes in pharmaceutical development for the U.S. cardiovascular market, marketing drugs like AGGRASTAT® and ZYPITAMAG®. The company operates Marley Drug, a pharmacy enhancing healthcare access nationwide.
Medicure announced the resignation of Board member Gerald McDole, effective January 31, 2023. McDole, who served since 2004, was recognized for his valuable contributions. Additionally, the company granted stock options totaling 1,205,000 shares at $1.25 each to directors, officers, and employees, pending approval from the TSX Venture Exchange. Medicure remains focused on its cardiovascular products in the U.S., including AGGRASTAT® and ZYPITAMAG®. The company aims to improve healthcare access through its pharmacy, Marley Drug, which serves various U.S. locations.
FAQ
What is the current stock price of Medicure (MCUJF)?
What is the market cap of Medicure (MCUJF)?
